This included a peptide, QYNPIRTTF, deriving from the master transcription regulator PHOX2B. Development of peptide-centric chimeric antigen receptors targeting this peptide resulted in selective killing of neuroblastoma cells and complete regression of neuroblastoma PDX tumors positive for PHOX2B [73••]. This evidence concerns the gene PHOX2B and neuroblastoma.